Quantcast

Investigation Report on China Pregabalin Market, 2009-2018

March 28, 2014

DUBLIN, March 28, 2014 /PRNewswire/ –

Dublin – Research and Markets (
http://www.researchandmarkets.com/research/qx6h7s/investigation) has announced the
addition of the “Investigation Report on China Pregabalin Market, 2009-2018″
[http://www.researchandmarkets.com/research/qx6h7s/investigation ] report to their
offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

Neuropathic pain is caused by damage or pathological changes of nervous system. Its
main features are dull pain, aestus and tingling. About 1% of people worldwide have
neuropathic pain. Epileptic seizures are the result of excessive and abnormal cortical
nerve cell activity in the brain. It is a group of long-term neurological disorders. As a
chronic disease, epilepsy can seriously damage patients’ mental and physical health and
become a huge burden for their families and the society. According to WHO, the global
number of epilepsy patients is higher than 50 million and over 9 million of them are in
China.

Pfizer Co., Ltd. submitted registration application for Pregabalin (produced by Pfizer
with the trade name “”Lyrica”") in the U.S. in 2003. In December 2004 pregabalin was
approved by FDA to treat diabetic neuropathic pain and postherpetic neuralgia. It is the
first drug approved to treat both the two diseases in the U.S.A. and in Europe. In June
2005, pregabalin was approved to be used in the adjuvant treatment of adults with
partial-onset seizures in epilepsy. After that, it was approved to treat generalized
anxiety disorder and fibromyalgia syndrome successively. Time Magazine named pregabalin as
one of the “”Top 10 Medical Progress”" in 2007. Total revenue of pregabalin is more than
USD 20 billion. The global sales revenue of Lyrica was approximately USD 4.16 billion,
increased by 13% YOY.

In 2010 Lyrica was approved to China. According to CRI’s market investigation, the
sales revenue of Lyrica in Chinese sample hospital market grew over 100 times from 2010 to
2013. Due to Lyrica’s success, many pharmaceutical manufacturers in China begin to apply
for pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd. received production
license in 2013. Lyrica produced by Pfizer is expected to be the main product in Chinese
market in recent years. However, its market share will decline in 2014 due to competition
from relatively cheap homemade drugs.

Key Topics Covered:

1 Relevant Concepts of Pregabalin

2 Market Overview of Pregabalin in China, 2010-2013

3 Investigation on Sales Value of Pregabalin in China, 2010-2013

4 Investigation on Market Share of Major Pregabalin Manufacturers in China, 2010-2013

5 Investigation on Market Size of Pregabalin by Dosage Form in China, 2010-2013

6 Reference Price Pregabalin in China Hospital Market, 2014

7 Major Manufacturing Enterprises in China Pregabalin Market, 2010-2014

8 Prospect of China Pregabalin Market, 2014-2018

Companies Mentioned:

        - Pfizer Deutschland GmbH
        - Chongqing Succeway Pharmaceutical Co., Ltd.

For more information visit

http://www.researchandmarkets.com/research/qx6h7s/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus